Caroline Pothet, Head of advanced therapies and haemato-oncology at the European Medicines Agency, shared a post by Dominik Karres, Scientific Officer at European Medicines Agency on LinkedIn, adding:
“Public consultation on EMA pediatric development guideline!
One of my first oncology assignment was contributing to the development and registration of a new medicine for pediatric T-ALL.
While this can be very rewarding, pediatric oncology drug development brings unique scientific and regulatory challenges – small populations, rare diseases, and the need to generate robust evidence while minimizing burden for children.
If you have expertise in this area, don’t wait any longer, go to and provide your feedback before the end of June.”
Quoting Dominik Karres‘s post:
“Important milestone! Open for public consultation!
This concept paper outlines high-level recommendations that drive the generation and assessment of meaningful proof-of-concept data to support the development of novel products in pediatric oncology.
Let us know your thoughts! It is key that all relevant perspectives are reflected in the future reflection paper!
Only through collaboration can we deliver!”
Other articles about Pediatric Oncology on OncoDaily.